Famine in Field Inspection

Famine in Field Inspection

April 2, 2005

News

Article

Pharmaceutical TechnologyPharmaceutical Technology-04-02-2005

Volume 29

Issue 4

What the industry needs most is not reduced oversight. What we need is, competent, constructive, informed, consistent, fair, and predictable inspection.

External Link - article-155381.pdf

Articles in this issue

Analytical Methods Validation In-Process Control Methods for the Manufacture of Active Pharmaceutical Ingredients

April 2005

Management Controls for GMP Compliance

The Sector Chart: A New Engineering Graph for Pharmaceutical Processes

Validation of Alternative Microbiology Methods for Product Testing Quantitative and Qualitative Assays

PAT and Process Understanding: A Call to Arms

Cold Chain Concerns

Evolutions in Direct Compression

X-ray Microtomography of Solid Dosage Forms

Orient Express

Importance of Background Microbial Levels in the Manufacture and Testing of Sterile Products

Using Visible Residue Limits for Introducing New Compounds into a Pharmaceutical Research Facility

Comparative Evaluation of Three Active Air Samplers for the Monitoring of Airborne Microorganisms

Famine in Field Inspection

Establishing Target Fills for Semisolid and Liquid Dosage Forms

Related Content

mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

Christopher Cole

June 12th 2025

Article

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

Patrick Lavery

June 11th 2025

Article

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024

Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

Patrick Lavery

June 10th 2025

Article

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.